News
April 6, 2026
Research and Development
Pharma Foods Co., Ltd. Acquires Exclusive Rights to Advance First-in-Class Adrenomedullin Program for CADASIL Across Key Asian Markets
March 23, 2026
Investor
Supplementary Materials of Consolidated Financial Results for the Six Months Ended January 31, 2026 
March 13, 2026
Investor
Notice Regarding Revision of Full-Year Financial Results Forecast for the Fiscal Year Ending July 2026
March 13, 2026
Investor
[Summary]Consolidated Financial Results for the Six Months Ended January 31, 2026 (Based on Japanese GAAP)
February 16, 2026
Investor
Notice Concerning Dividends of Surplus (Interim Dividend)
March 13, 2026
Investor
Notice Regarding Revision of Full-Year Financial Results Forecast for the Fiscal Year Ending July 2026
March 13, 2026
Investor
[Summary]Consolidated Financial Results for the Six Months Ended January 31, 2026 (Based on Japanese GAAP)
February 16, 2026
Investor
Notice Concerning Dividends of Surplus (Interim Dividend)